Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials
call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or
email cancerclinicaltrials@bsd.uchicago.edu.

This is a study of pembrolizumab (MK-3475) as first-line treatment for participants with
advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Participants will be
randomly assigned to one of the 3 treatment arms of the study: pembrolizumab as monotherapy,
or pembrolizumab + cisplatin + 5-fluorouracil (5-FU) or capecitabine, or placebo + cisplatin
+ 5-FU or capecitabine. The primary hypothesis is that pembrolizumab provides a clinically
meaningful progression free and/or overall survival.